Bleeding and venous thromboembolism in the critically ill with emphasis on patients with renal insufficiency

Current Opinion in Pulmonary Medicine

Volumn 15, Issue 5, 2009, Pages 455-462

  Cook, Deborah J ^a,b,c   Douketis, James ^a,b   Arnold, Donald ^a   Crowther, Mark A ^a  

^a Department of Medicine ^*  (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Prevention; Renal failure; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; RANITIDINE; SUCRALFATE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; APACHE; ARTIFICIAL VENTILATION; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DEEP VEIN THROMBOSIS; DISEASE PREDISPOSITION; DISEASE SEVERITY; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG EMBOLISM; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; THROMBOEMBOLISM; THROMBOSIS PREVENTION; UPPER GASTROINTESTINAL BLEEDING; VENOUS THROMBOEMBOLISM;

CRITICAL ILLNESS; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEMOSTATICS; HUMANS; INCIDENCE; RENAL INSUFFICIENCY; RISK FACTORS; SURVIVAL RATE; VENOUS THROMBOEMBOLISM;

EID: 68949189297     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32832ea4dd     Document Type: Review

References (38)

1. Attia J, Ray J, Cook DJ, et al. Deep venous thrombosis and its prevention in critically ill adults. Arch Intern Med 2001; 161'1268-1279.
2. Cook DJ, Crowther M, Meade M, et al. Deep venous thrombosis in medical-surgical ICU patients: prevalence, incidence and risk factors. Crit Care 2003; 20 (Suppl 2):309-313.
3. Cook DJ, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med 1998; 338:791-797.
4. Fraisse F, Holzapfel L, Couland JM, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000; 161 (4 Pt 1):1109-1114.
5. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein Cfor severe sepsis. N Engl J Med 2001; 344:699-709.
6. Arnold DM, Donahoe L, Clarke FJ, et al. Bleeding during critical illness: a prospective cohort study using a new measurement tool. Clin Invest Med 2007; 30:E93-E102.
7. Raskob G, Kearon C, Geerts W, et al. Evaluating bleeding complications of thromboprophylaxis after hip replacement: a systematic review. J Thromb Haemost 2003; 1 (Suppl 1): abstract number P1860.
8. Koreth R, Weinert C, Weisdorf DJ, Key NS. Measurement of bleeding severity: a critical review. Transfusion 2004; 44:605-617.
9. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
10. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114:774-782.
11. Nevo S, Swan V, Enger C, et al. Acute bleeding after bone marrow transplantation (BMT): incidence and effect on survival. A quantitative analysis in 1402 patients. Blood 1998; 91:1469-1477.
12. Cook DJ, Douketis J, Meade M, et al. for the Canadian Critical Care Trials Group. Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency: prevalence, incidence and risk factors. Crit Care 2008; 12:R32-1-9.
13. Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol 2004; 15:3192-3206.
14. Sohal AS, Gangji AS, Crowther MA, Treleaven D. Uremic bleeding: patho-physiology and clinical risk factors. Thromb Res 2006; 118:41 7-422.
15. Remuzzi G, Perico N, Zoja C, et al. Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. J Clin Invest 1990; 86:1768-1771.
16. Eknoyan G, Brown CH 3rd. Biochemical abnormalities of platelets in renal failure. Evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adenosine triphosphatase. Am J Nephrol 1981; 1:17-23.
17. Zwaginga JJ, IJsseldijk MJ, de Groot PG, et al. Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma. Arterioscler Thromb 1991; 11:733-744.
18. Yusuf S,ZhaoF, MehtaSR, etal., Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.
19. Anderson RJ, O'brien M, MaWhinney S, et al. Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery. VA Cooperative Study #5. Kidney Int 1999; 55:1057-1062.
20. Horst M, Mehlhorn U, Hoerstrup SP, et al. Cardiac surgery in patients with end-stage renal disease: 10-year experience. Ann Thorac Surg 2000; 69:96-101.
21. Liu JY, Birkmeyer NJ, Sanders JH, et al. Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation 2000; 102: 2973-2977.
22. Crowther M, Cook D, Griffith L, etal. Deep venous thrombosis: clinically silent in the intensive care unit. J Crit Care 2005; 20:334-340.
23. Cook DJ, Rocker G, Meade MO, et al., for the PROTECT Investigators and the Canadian Critical Care Trials Group. Prophylaxis of ThromboEmbolism in Critical Care Trials (PROTECT): a pilot study. J Crit Care 2005; 20:364-372. (Pubitemid 41727596)
24. Cook DJ, Crowther M, Meade M, et al. Deep venous thrombosis in medical-surgical ICU patients: prevalence, incidence and risk factors. Crit Care Med 2005; 33:1565-1571. (Pubitemid 40980613)
25. Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 1995; 274: 335-337.
26. Irish AB, Green FR. Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: relationship with dyslipidaemia, inflammation, and factor VII genotype. Nephrol Dial Transplant 1998; 13:679-684.
27. Tveit DP, Hypolite IO, Hshieh P, etal. Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis 2002; 39:1011-1017. (Pubitemid 34454219)
28. Wun T, Law L, Harvey D, et al. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 2003; 98:1514-1520.
29. Steurer M, Sudmeier I, Stauder R, Gastl G. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol 2003; 121:101-103.
30. Corwin HL, Gettinger A, Fabian TC, etal. Efficacy and safety of erythropoietin in the critically ill. N Engl J Med 2007; 357:965-976.
31. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688-699.
32. Ravaud P, Durieux P, Fourcade A, and the Comite Scientifique Thrombose AP-HP. Prophylaxis of postoperative venous thrombosis: recommendations from l'assistance publique des hospitaux de Paris. Sangue Thromb Vaisseaux 1995; 7:119-129.
33. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 2002; 162:2605-2609.
34. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl):338S-400S.
35. Rabbat C, Cook DJ, Crowther MA. Dalteparin thromboprophylaxis for critically ill medical-surgical patients. J Crit Care 2005; 20:357-363.
36. Douketis J, Cook DJ, Meade M, et al., for the Canadian Critical Care Trials Group. Renal insufficiency with the low-molecular-weight heparin dalteparin: An assessment of safety and pharmacodynamics. The DIRECT (Dalteparin's Influence on REnally Compromised anti-Ten-A) Study. Arch Intern Med 2008; 168:1805-1812.
37. Kani C, Markantonis SL, Nicolaou C, Maggina N. Monitoring of subcutaneous dalteparin in patients with renal insufficiency under intensive care: an observational study. J Crit Care 2006; 21:79-84; 38.
38. Tincani E, Mannucci C, Casolari B, et al. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica 2006; 97:976-979.